newsfilter
← Latest News
GlobeNewswire·

MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in